Volume 6.11 | Mar 27

Cord Blood News 6.11 March 27, 2014
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
 
TOP STORY
Umbilical Cord Blood-Derived Mesenchymal Stem Cells Seeded onto Fibronectin-Immobilized PCL Nanofiber Improve the Cardiac Function
Scientists investigated whether umbilical cord blood-derived mesenchymal stem cell-seeded fibronectin-immobilized polycaprolactone (PCL) nanofibers could improve cardiac function and inhibit left ventricle remodeling in a rat model of myocardial infarction. [Acta Biomater] Abstract
New Cord Banking Software Solution from STEMSOFT
 
PUBLICATIONS (Ranked by impact factor of the journal)
Cord Blood Mesenchymal Stem Cells Suppress DC-T Cell Proliferation via ProstaglandinB2
Investigators found that cord blood mesenchymal stem cells (MSC) themselves are hardly immunogenic as tested with allogeneic T-cells. Dendritic cells (DCs) cocultured with second party T-cells evoked abundant proliferation that was inhibited by third party cord blood MSC. Optimal inhibition was seen with one cord blood MSC for every dendritic cell. [Stem Cells Dev] Abstract

Umbilical Cord Mesenchymal Stem Cell Transplantation in Active and Refractory Systemic Lupus Erythematosus: A Multicenter Clinical Study
Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) have shown a good safety profile and therapeutic effect in severe and refractory systemic lupus erythematosus (SLE) in the authors’ single-center pilot study. The present multicenter clinical trial was undertaken to assess the safety and efficacy of allogenic UC-MSC transplantation in active and refractory SLE patients. [Arthritis Res Ther] Abstract | Full Article

Neurotherapeutic Effect of Cord Blood Derived CD45+ Hematopoietic Cells in Mice after Traumatic Brain Injury
Cell therapy by human umbilical cord blood (HUCB) has shown promising results in animal models of traumatic brain injury (TBI) and is under evaluation in clinical trials. HUCB contains different cell populations, but to date only mesenchymal stem cells have been evaluated for therapy of TBI. The authors present the neurotherapeutic effect, as evaluated by neurological score, using a single dose of HUCB-derived mononuclear cells upon intravenous administration one day post-trauma in a mouse model of closed head injury. [J Neurotrauma] Abstract

The Anti-Oxidative Role of Micro-Vesicles Derived from Human Wharton-Jelly Mesenchymal Stromal Cells through NOX2/gp91(phox) Suppression in Alleviating Renal Ischemia-Reperfusion Injury in Rats
Scientists hypothesized that micro-vesicles derived from human Wharton Jelly mesenchymal stromal cells could protect kidney against ischemia/reperfusion injury through mitigating oxidative stress. [PLoS One] Full Article

Comparison of Articular Cartilage Repair with Different Hydrogel-Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Composites in a Rat Model
The authors aimed to explore the feasibility and efficacy of articular cartilage repair using composites of human umbilical cord blood derived mesenchymal stem cells and four different hydrogels in a rat model. [Stem Cell Res Ther] Abstract | Full Article

Microvesicles Derived from Human Wharton’s Jelly Mesenchymal Stromal Cells Ameliorate Renal Ischemia-Reperfusion Injury in Rats by Suppressing CX3CL1
Scientists focused on the therapeutic effects of human Wharton-Jelly mesenchymal stromal cell derived microvesicles in renal ischemia-reperfusion injury and its potential mechanisms. [Stem Cell Res Ther]
Abstract
| Full Article

Characterization and In-Vitro Differentiation Potency of Early-Passage Canine Amnion- and Umbilical Cord-Derived Mesenchymal Stem Cells as Related to Gestational Age
The authors cytogenetically and molecularly characterized and followed the in vitro proliferation and differentiation potential of early-passage canine amniotic membrane mesenchymal stem cells (MSCs) and umbilical cord matrix MSCs isolated from fetuses at early (35-40 days) and late (45-55 days) gestational ages. [Mol Reprod Dev] Abstract

Low Immunogenicity of Allogeneic Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells In Vitro and In Vivo
Researchers showed that allogeneic human umbilical cord blood derived-mesenchymal stem cells (hUCB-MSCs) maintained low immunogenicity even after immune challenge in vitro. To confirm these properties in vivo, a humanized mouse model was established by injecting isolated hUCB-derived CD34+ cells intravenously into immunocompromised NOD/SCID IL2γnull mice. [Biochem Biophys Res Commun] Abstract

Hematopoietic Course for Cord Blood - Learn More and Register
 
REVIEWS
Cord Blood Banking and Transplantation: Advances and Controversies
A review of articles published since January 2012 on the topic of cord blood banking and cord blood stem cell transplantation was conducted for this the 25th anniversary year of the first cord blood transplant performed in a human. [Curr Opin Pediatr] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
 
INDUSTRY NEWS
Dr. Mary Horowitz Presented with Lifetime Achievement Award for Blood and Marrow Transplant Research
Mary Horowitz, MD, MS, the Robert A. Uihlein, Jr. Chair in Hematologic Research, professor of medicine and chief of hematology and oncology at the Medical College of Wisconsin, was presented with the 2014 Lifetime Achievement Award by the American Society for Blood and Marrow Transplantation. [Medical College of Wisconsin] Press Release

Cord Blood Registry’s Newborn Possibilities Program
For families that have been identified with a qualifying medical condition currently treatable with a cord blood stem cell transplant or a high-risk pregnancy, the Newborn Possibilities Program provides no-cost newborn stem cell processing and five years of storage. [PR Newswire Association LLC] Press Release

Cesca Therapeutics Submits Pre-IDE Information Package to FDA for Surgwerks(TM) CLI therapy System
Cesca Therapeutics, Inc., an autologous cell based regenerative medicine company, announced it has submitted a pre-IDE (Investigational Device Exemption) information package to the U. S. Food and Drug Administration (FDA) for the use of the SurgWerks™ CLI Therapy designed to treat no option patients with late stage critical limb ischemia (CLI). [GlobeNewswire, Inc.] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 12th International Cord Blood Symposium
June 5-7, 2014
San Francisco, United States

Visit our events page to see a complete list of events in the cord blood community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Hematopoietic Stem Cell and Leukemia Research (City of Hope)

Postdoctoral Position – Hematopoietic Stem Cell & Neutrophil Cell Polarity (Cincinnati Children’s Hospital Medical Center)

Cell Therapy Lab Technologist II (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Mammalian Hematopoietic and Erythroid Development (The Icahn School of Medicine at Mount Sinai)

Postdoctoral Position – Human Stem Cell Biology and Hematopoiesis (Johns Hopkins University School of Medicine)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Director – Clinical Immunogenetics Laboratory (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Hematopoietic Stem Cell Biology (St. Jude Children’s Research Hospital)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us